• 咨询热线
    客服服务热线 13671568941/15317326293
  • 在线咨询
  • 微信客服
    微信客服
  • 公众号
    扫码关注公众号

SCIO-469

CAS No. 309913-83-5

SCIO-469 ( Talmapimod | SCIO469 | SCIO 469 )

产品货号. M13991 CAS No. 309913-83-5

一种有效的选择性 p38α MAPK 抑制剂,IC50 为 9 nM。

纯度: >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
规格 价格/人民币 库存 数量
2MG ¥567 有现货
5MG ¥948 有现货
10MG ¥1515 有现货
25MG ¥3216 有现货
50MG ¥4771 有现货
100MG ¥6828 有现货
200MG 获取报价 有现货
500MG 获取报价 有现货
1G 获取报价 有现货

生物学信息

  • 产品名称
    SCIO-469
  • 注意事项
    本公司产品仅用于科研实验,不得用于人体或动物的临床与诊断
  • 产品简述
    一种有效的选择性 p38α MAPK 抑制剂,IC50 为 9 nM。
  • 产品描述
    A potent, selective p38α MAPK inhibitor with IC50 of 9 nM; displays 10-fold selectivity for p38α over p38β, >2,000-fold selectivity over a panel of 20 other kinases, including other MAP kinases; decreases apoptosis in MDS CD34+ progenitors and leads to dose-dependant increases in erythroid and myeloid colony formation; enhances the ability of MG132 and bortezomib to induce the apoptosis of MM cells, and inhibits tumor growth in vivo.Rheumatoid Arthritis Phase 2 Discontinued.
  • 体外实验
    Talmapimod (SCIO-469) (100-200 nM; 1 hour) inhibits phosphorylation of p38 MAPK in MM cells.Talmapimod inhibits LPS-induced TNF-a production in human whole blood.Talmapimod decreases constitutive p38alpha MAPK phosphorylation of both 5T2MM and 5T33MM cells.Western Blot Analysis Cell Line:MM.1S, U266, RPMI8226, MM.1R, and RPMI-Dox40 cell lines Concentration:100, 200 nM Incubation Time:1 hour Result:Strongly inhibits phosphorylation of p38 MAPK.
  • 体内实验
    Targeting p38α MAPK with Talmapimod (SCIO-469) decreases myeloma burden in addition to preventing the development of myeloma bone disease.Talmapimod inhibits multiple myeloma growth and prevents bone disease in the 5T2MM and 5T33MM models.Talmapimod (10-90 mg/kg; p.o.; twice daily orally for 14 days) dose-dependently reduced tumor growth and also dose-dependently reduced weight of the palpable tumors at termination. Animal Model:Six-week-old male triple immune-deficient BNX mice (RPMI-8226 MM palpable tumors)Dosage:P.o.; twice daily orally for 14 days Administration:10, 30, 90 mg/kg Result:Dose-dependently reduced tumor growth.
  • 同义词
    Talmapimod | SCIO469 | SCIO 469
  • 通路
    MAPK/ERK Signaling
  • 靶点
    p38 MAPK
  • 受体
    p38 MAPK
  • 研究领域
    Inflammation/Immunology
  • 适应症
    Rheumatoid Arthritis

化学信息

  • CAS Number
    309913-83-5
  • 分子量
    513.0035
  • 分子式
    C27H30ClFN4O3
  • 纯度
    >98% (HPLC)
  • 溶解度
    10 mM in DMSO
  • SMILES
    CC1CN(C(CN1C(=O)C2=C(C=C3C(=C2)C(=CN3C)C(=O)C(=O)N(C)C)Cl)C)CC4=CC=C(C=C4)F
  • 化学全称
    1H-Indole-3-acetamide, 6-chloro-5-[[(2R,5S)-4-[(4-fluorophenyl)methyl]-2,5-dimethyl-1-piperazinyl]carbonyl]-N,N,1-trimethyl-α-oxo-

运输与储存

  • 储存条件
    (-20℃)
  • 运输条件
    With Ice Pack
  • 稳定性
    ≥ 2 years

参考文献

1. Navas TA, et al. Leukemia. 2006 Jun;20(6):1017-27. 2. Navas TA, et al. Blood. 2006 Dec 15;108(13):4170-7. 3. Hideshima T, et al. Oncogene. 2004 Nov 18;23(54):8766-76.
产品手册
关联产品
  • Rosin

    松香是一种天然产品,可能具有治疗炎症的潜力。

  • LY2228820 dimesylate

    LY2228820 dimesylate (Ralimetinib) 是一种有效的、选择性的、口服的 p38 MAPK 抑制剂,对 p38α 和 p38β 的 IC50 分别为 5.3 和 3.2 nM。

  • MW181 hydrochloride

    MW181 (MW01-10-181SRM) 是一种异构体选择性、脑渗透性、口服生物可利用的 p38α MAPK 小分子抑制剂,Ki 为 184 nM。